Cholecystokinin (CCK) and CCK receptor expression by human gliomas: Evidence for an autocrine/paracrine stimulatory loop

Neuropeptides

Volumn 42, Issue 3, 2008, Pages 255-265

  Oikonomou, Eftychia ^a   Buchfelder, Michael ^b   Adams, Eric F ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Autocrine; CCK antagonists; CCK receptors; Cholecystokinin; Gliomas; Paracrine

Indexed keywords

CASPASE 3; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; L 36260; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEASOME; PROTEIN KINASE C;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL GROWTH; CELL LINE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION;

AUTOCRINE COMMUNICATION; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECYSTOKININ; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; HUMANS; HYDROLYSIS; PARACRINE COMMUNICATION; PHOSPHATIDYLINOSITOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, CHOLECYSTOKININ; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE;

EID: 44649187382     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2008.02.005     Document Type: Article

References (39)

1. Adams E.F., Lei T., Buchfelder M., Bowers C.Y., and Fahlbush R. Protein kinase C-dependant growth hormone releasing peptides stimulate cyclic adenosine 3′,5′-monophosphate production by human pituitary somatotrophinomas expressing gsp oncogenes: evidence for cross-talk between transduction pathways. Mol. Endocrinol. 10 (1996) 434-443
2. Adams E.F., Lei T., Buchfelder M., Petersen B., and Fahlbush R. Biochemical characterisation of human pituitary somatotrophinomas with and without gsp mutations: in vitro cells culture studies. J. Clin. Endocrinol. Metab. 80 (1995) 2077-2081
3. Baldwin J.M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12 (1993) 1693-1703
4. Behin A., Hoang-Xuan K., Carpentier A.F., and Delattre J.Y. Primary brain tumours in adults. Lancet 361 (2003) 323-331 Review
5. Bold R.J., Alpard S., Ishizuka J., Townsend Jr. C.M., and Thompson J.C. Growth-regulatory effect of gastrin on human colon cancer cell lines is determined by protein kinase a isoform content. Regul. Pept. 53 (1994) 61-70
6. Camby I., Salmon I., Danguy A., Pasteels J.L., Brotchi J., Martinez J., and Kiss R. Influence of gastrin on human astrocytic tumour cell proliferation. J. Natl. Cancer Inst. 88 (1996) 594-600
7. Choi H.J., Kim H.H., Lee H.S., Huh G.Y., Seo S.Y., Jeong J.H., Kim J.M., and Yoo Y.H. Lactacystin augments the sulindac-induced apoptosis in HT-29 cells. Apoptosis 8 (2003) 301-305
8. Doi R., Inoue K., Kogire M., Sumi S., Yun M., Futaki S., Fujii N., Yajima H., and Tobe T. Role of sulphated tyrosine residue in influencing the biologic activity of human cholecystokinin-33. Biochem. Biophys. Res. Commun. 153 (1988) 1209-1213
9. Drexler H.C. Activation of the cell death program by inhibition of proteasome function. PNAS 94 (1997) 855-860
10. Drosopoulos K.G., Roberts M.L., Cermak L., Sasazuki T., Shirasawa S., Andera L., and Pintzas A. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J. Biol. Chem. 280 (2005) 22856-22867
11. Frederick L., Wang X.Y., Eley G., and James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60 (2000) 1383-1387
12. Garkavtsev I., Kozin S.V., Chernova O., Xu L., Winkler F., Brown E., Barnett G.H., and Jain R.K. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428 (2004) 328-332
13. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., and Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA 87 (1990) 6728-6732
14. Iversen P.O., Rodwell R.L., Pitcher L., Taylor K.M., and Lopez A.F. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic cells by the granulocyte macrophage colony-stimulating factor analogue E21R. Blood 88 (1996) 2634-2639
15. Jensen R.T., Qian J.M., Lin J.T., Mantey S.A., Pisegna J.R., and Wank R.A. Distinguishing multiple CCK receptor subtypes. Studies with guinea pig chief cells and transfected human CCK receptors. Ann. NY. Acad. Sci. 713 (1994) 88-106
16. Kaufmann R., Lindschau C., Schoneberg T., Haller H., Henklein P., Boomgaarden M., and Ott T. Type B cholecystokinin receptors on rat glioma C6 cells. Binding studies and measurement of intracellular calcium mobilization. Brain Res. 639 (1994) 109-114
17. 6 cells. Neuropeptides 32 (1998) 185-189
18. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1 (1999) 44-51
19. Kopin A.S., McBride E.W., Quinn S.M., Kolakowski Jr. L.F., and Beinborn M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J. Biol. Chem. 270 (1995) 5019-5023
20. Lefranc F., Camby I., Belot N., Bruyneel E., Chaboteaux C., Brotchi J., Mareel M., Salmon I., and Kiss R. Gastrin significantly modifies the migratory abilities of experimental glioma cells. Lab Invest 82 (2002) 1241-1252
21. C) in human tumours of the central and peripheral nervous system. Int. J. Oncol. 22 (2003) 213-219
22. Liddle R.A., Elashoff J., and Reeve Jr. J.R. Relative bioactivities of cholecystokinins-8 and -33 on rat pancreatic acini. Peptides 7 (1986) 723-727
23. Moran T.H., Robinson P.H., Goldrich M.S., and McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362 (1986) 175-179
24. Noble F., Wank S.A., Crawley J.N., Bradwejn J., Seroogy K.B., Hamon M., and Roques B.P. International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. 51 (1999) 745-781
25. Orino E., Tanaka K., Tamura T., Sone S., Ogura T., and Ichihara A. ATP-dependent reversible association of proteasomes with multiple protein components to form 26S complexes that degrade ubiquitinated proteins in human HI-60 cells. FEBS Lett. 284 (1991) 206-210
26. Orlowski R.Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6 (1999) 303-313 Review
27. Pannequin J., Oiry C., Morel C., Kucharczak J., Camby I., Kiss R., Gagne D., Galleyrand J.C., and Martinez J. C-terminal heptapeptide of gastrin inhibits astrocytomas motility by interacting with a new gastrin binding site. Pharmacology 302 (2002) 274-282
28. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev. 24 (2003) 389-427
29. Reubi J.C. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J. Nucl. Med. 36 (1995) 1825-1835 Review
30. Roerig S.C., Williams C.L., Hruby V.J., Burks T.F., and Rosenfeld G.C. Inhibition of adenylyl cyclase by the cholecystokinin analog SNF 9007 in neuroblastoma X glioma NG108-15 hybrid cells. Reg. Pept. 61 (1996) 51-56
31. Roettger B.F., Ghanekar D., Rao R., Toledo C., Yingling J., Pinon D., and Miller L.J. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51 (1997) 357-362
32. Roettger B.F., Rentsch R.U., Pinon D., Holicky E., Hadac E., Larkin J.M., and Miller L.J. Dual pathways of internalization of the cholecystokinin receptor. J. Cell Biol. 128 (1995) 1029-1041
33. Rozen S., and Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S., and Misener S. (Eds). Bioinformatics Methods and Protocols: Methods in Molecular Biology (2000), Humana Press, Totowa, NJ 365-386
34. Sadoul R., Fernandez P.A., Quiquerez A.L., Martinou I., Maki M., Schroter M., Becherer J.D., Irmler M., Tschopp J., and Martinou J.C. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15 (1996) 3845-3852
35. Shulkes A., and Baldwin G.S. Biology of gut cholecystokinin and gastrin receptors. Clin. Exp. Pharmacol. Physiol. 24 (1997) 209-216
36. Solomon T.E., Yamada T., Elashoff J., Wood J., and Beglinger C. Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33. Am. J. Physiol. 247 (1984) G105-G111
37. Townsend C.M., Singh P., and Thompson J.C. Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 91 (1986) 1002-1006
38. Valle J. CCK receptor trafficking: a novel paradigm of travel. Focus on regulation of lateral mobility and cellular trafficking of the CCK receptor by a partial agonist. Am. J. Physiol. Cell Physiol. 276 (1999) C537-C538 Review
39. Watanabe K., Tachibana O., Sata K., Yonekawa Y., Kleihues P., and Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6 (1996) 217-224